A5000247698- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Healthcare cost, quality, practices
- Healthcare Policy and Management
- Economic and Financial Impacts of Cancer
- Pharmaceutical studies and practices
- Pharmaceutical industry and healthcare
- Statistical Methods in Clinical Trials
- Geriatric Care and Nursing Homes
- Global Health Care Issues
- Dementia and Cognitive Impairment Research
- Heavy Metal Exposure and Toxicity
- Lymphoma Diagnosis and Treatment
- Air Quality and Health Impacts
- Cardiac pacing and defibrillation studies
- Frailty in Older Adults
- Chronic Disease Management Strategies
- Primary Care and Health Outcomes
- Energy, Environment, and Transportation Policies
- Pharmaceutical Practices and Patient Outcomes
- Aortic aneurysm repair treatments
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Heavy metals in environment
- Delphi Technique in Research
Tufts Medical Center
2016-2025
Tufts University
2015-2024
RELX Group (United States)
2021
University of York
2020
University of North Carolina at Chapel Hill
2015-2020
Sage Therapeutics (United States)
2020
University of Maryland, College Park
2020
Alzheimer's Drug Discovery Foundation
2017
Memorial Sloan Kettering Cancer Center
2015
Rogers (United States)
2013
The ratio of $50,000 per quality-adjusted life-year (QALY) gained by using a given health care intervention has long served as benchmark for the value U.S. care. But evidence suggests that it is too low and might best be thought an implied lower boundary.
A popular component of the candidates' plans for controlling spiraling health care costs involves greater promotion preventive measures. Joshua Cohen, Peter Neumann, and Milton Weinstein write that sweeping statements about cost-saving potential prevention, however, are overreaching.
Our objective was to examine perspective and costing approaches used in cost-effectiveness analyses (CEAs) the distribution of reported incremental ratios (ICERs).
Dementia is often underdiagnosed and this problem more common among some ethnoracial groups.The objective of study was to examine racial ethnic disparities in the timeliness receiving a clinical diagnosis dementia.This prospective cohort study.A total 3966 participants age 70 years above with probable dementia Health Retirement Study, linked their Medicare Medicaid claims.We performed logistic regression compare likelihood having missed or delayed claims by race/ethnicity. We analyzed...
udden cardiac death (SCD) in the young (SCDY) has a devastating impact on families, care providers, and community attracts significant public media attention.Sudden is defined as an abrupt unexpected due to cardiovascular cause, typically occurring Ͻ1 hour from onset of symptoms.Depending source, "young" variably those less than 25, 30, 35, or 40 years age.][3] Sudden infant syndrome (SIDS) may be related SCD some infants.Sudden sudden year age that cannot explained after thorough...
Interview with Dr. Peter Neumann on the use of various new value-based frameworks for assessing drugs and drug prices. (08:22)Download Escalating prices have spawned a flurry initiatives designed to help physicians, payers, patients understand value therapies make better choices about their use. But these efforts revealed numerous analytic implementation challenges.
To determine what thresholds are most often cited in the cost-effectiveness literature for low- and middle-income countries (LMICs), given various recommendations proposed used to date, thereafter assess whether studies appropriately justified their use of threshold values.We reviewed contents Tufts Medical Center Global Health Cost-Effectiveness Analysis Registry, a repository all English language cost-per-disability-adjusted life-year averted indexed PubMed. Our review included catalogued...
This Viewpoint reviews the rationale for measuring health outcomes using quality-adjusted life-years (QALYs) and discusses advantages limitations of measure its role in attempts to define promote practice high-value medicine.
Individuals with Alzheimer's disease and related disorders (ADRD) have more frequent hospitalizations than individuals without ADRD, some of these admissions may be preventable proactive outpatient care.This study was a cross-sectional analysis Medicare claims data from 195,024 fee-for-service ADRD beneficiaries aged ≥65 years an equal number matched non-ADRD controls drawn the 5% random sample in 2007-2008. We analyzed proportion patients potentially avoidable (PAHs, as defined by...
SUMMARY We assessed how much, if anything, people would pay for a laboratory test that predicted their future disease status. A questionnaire was administered via an internet‐based survey to random sample of adult US respondents. Each respondent answered questions about two different scenarios, each which specified: one four randomly selected diseases (Alzheimer's, arthritis, breast cancer, or prostate cancer); ex ante risk developing the (randomly designated 10 25%); and accuracy perfect...
Hemodialysis vascular access recommendations promote arteriovenous (AV) fistulas first; however, it may not be the best approach for all hemodialysis patients, because likelihood of successful fistula placement, procedure-related and subsequent costs, patient survival modify optimal choice. We performed a decision analysis evaluating AV fistula, graft, central venous catheter (CVC) strategies patients initiating with CVC, scenario occurring in over 70% United States dialysis patients. A tree...
Background: Targeting low-dose computed tomography (LDCT) for lung cancer screening to persons at highest risk mortality has been suggested improve efficiency. Objective: To quantify the value of risk-targeted selection compared with National Lung Screening Trial (NLST) eligibility criteria. Design: Cost-effectiveness analysis using a multistate prediction model. Data Sources: NLST. Target Population: Current and former smokers eligible screening. Time Horizon: Lifetime. Perspective: Health...
Abstract Based on imperfect data and theory, agencies such as the United States Environmental Protection Agency (USEPA) currently derive "reference doses" (RfDs) to guide risk managers charged with ensuring that human exposures chemicals are below population thresholds. The RfD for a chemical is typically reported single number, even though it widely acknowledged there significant uncertainties inherent in derivation of this number. In article, authors propose probabilistic alternative EPA's...